Summary

The global Transdermal Preparation market size is predicted to grow from US$ 42824 million in 2025 to US$ 53564 million in 2032; it is expected to grow at a CAGR of 3.3% from 2026 to 2032.
Transdermal preparations refer to a dosage form that delivers drugs into the systemic circulation or local tissues through the skin as a route of administration in the form of patches, gels, plasters, microneedles or hot melt adhesive systems, achieving sustained release, stable blood drug concentration or local targeted therapy. They are widely used in pain relief, hormone replacement, cardiovascular diseases, smoking cessation and neurological disorders treatment. The core advantages are non-invasive administration and improved patient compliance. The global sales volume is expected to reach approximately 1.92 billion units in 2025, with an average unit price of about 22.8 US dollars and a capacity utilization rate of around 87%. The upstream mainly consists of raw material drug enterprises, suppliers of polymer materials and pressure-sensitive adhesives, transdermal enhancers and functional excipients. The midstream includes formulation development and patch manufacturing enterprises. The downstream comprises pharmaceutical companies, hospitals, chain pharmacies and home medical channels. The industry's gross profit margin is typically between 55% and 75%, with high-end microneedles and long-acting controlled-release products exceeding 75%. In the product cost structure, raw materials and functional excipients account for about 38% to 45%, polymer substrates and pressure-sensitive adhesives about 22%, process development and R&D costs about 15%, production and quality control about 10%, and packaging, distribution channels and logistics about 8% to 12%.
The transdermal preparation industry is currently at a critical stage of upgrading from traditional sustained-release patches to high-end intelligent delivery systems. Its core growth drivers come from the continuous expansion of long-term medication needs for chronic diseases and the healthcare system's increasing preference for non-invasive treatment solutions. Structurally, the low-end mature patch market is growing steadily, while microneedles, intelligent controlled-release, and composite delivery systems are becoming the main growth engines. In the future, competition will shift from single formulations to integrated solutions combining drugs and delivery systems, with significant increases in technical barriers. As the integration of materials science, bioengineering, and smart medical technology deepens, the role of transdermal preparations in precision medicine will be further enhanced. At the same time, pharmaceutical companies are accelerating the development of long-acting formulations and differentiated drug delivery pathways to improve lifecycle management capabilities. Overall, the industry still has strong potential for technological advancement and structural upgrading, with a clear long-term growth logic, and is expected to continue expanding under the backdrop of global aging and chronic disease management demands.
LP Information, Inc. (LPI) ' newest research report, the “Transdermal Preparation Industry Forecast” looks at past sales and reviews total world Transdermal Preparation sales in 2025, providing a comprehensive analysis by region and market sector of projected Transdermal Preparation sales for 2026 through 2032. With Transdermal Preparation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transdermal Preparation industry.
This Insight Report provides a comprehensive analysis of the global Transdermal Preparation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Transdermal Preparation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Transdermal Preparation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transdermal Preparation and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transdermal Preparation.
This report presents a comprehensive overview, market shares, and growth opportunities of Transdermal Preparation market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Injectable Preparations
Non Injectable Preparations
Segmentation by Dosage Form:
Patch
Cataplasm Hydrogel Patch
Hot Melt Adhesive Patch
Other
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
3M (US)
AdhexPharma (FR)
Bayer AG (DE)
Boehringer Ingelheim (DE)
Corium (US)
Endo International (IE)
GlaxoSmithKline (GSK) (GB)
Grünenthal Group (DE)
Henkel (DE)
Hisamitsu Pharmaceutical (JP)
IBSA Group (CH)
Johnson & Johnson (US)
Luye Pharma Group (HK)
LTS Lohmann Therapie-Systeme AG (DE)
Mitsubishi Tanabe Pharma Corporation (JP)
Mundipharma (GB)
Mylan (Viatris) (US)
Nitto Denko Corporation (JP)
Noven Pharmaceuticals (US)
Novartis AG (CH)
Perrigo Company plc (IE)
ProSolus, Inc. (US)
Purdue Pharma L.P. (US)
Scilex Pharmaceuticals (US)
Sino-American Tianjin Squibb (CN)
SOLA Pharmaceuticals (US)
Sun Pharmaceutical Industries Ltd. (IN)
Tapemark (US)
Teikoku Seiyaku Co., Ltd. (JP)
Teva Pharmaceutical Industries Ltd. (IL)
UCB Pharma (BE)
Upsher-Smith Laboratories (US)
Henan Lingrui Pharmaceutical Co., Ltd. (CN)
Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN)
Key Questions Addressed in this Report
What is the 10-year outlook for the global Transdermal Preparation market?
What factors are driving Transdermal Preparation market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Transdermal Preparation market opportunities vary by end market size?
How does Transdermal Preparation break out by Type, by Application?

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Transdermal Preparation Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Transdermal Preparation by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Transdermal Preparation by Country/Region, 2021, 2025 & 2032
2.2 Transdermal Preparation Segment by Type
2.2.1 Injectable Preparations
2.2.2 Non Injectable Preparations
2.2.3 Transdermal Preparation Sales by Type
2.2.3.1 Global Transdermal Preparation Sales Market Share by Type (2021-2026)
2.2.3.2 Global Transdermal Preparation Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Transdermal Preparation Sale Price by Type (2021-2026)
2.3 Transdermal Preparation Segment by Dosage Form
2.3.1 Patch
2.3.2 Cataplasm Hydrogel Patch
2.3.3 Hot Melt Adhesive Patch
2.3.4 Other
2.3.5 Transdermal Preparation Sales by Dosage Form
2.3.5.1 Global Transdermal Preparation Sales Market Share by Dosage Form (2021-2026)
2.3.5.2 Global Transdermal Preparation Revenue and Market Share by Dosage Form (2021-2026)
2.3.5.3 Global Transdermal Preparation Sale Price by Dosage Form (2021-2026)
2.4 Transdermal Preparation Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.4.4 Transdermal Preparation Sales by Application
2.4.4.1 Global Transdermal Preparation Sale Market Share by Application (2021-2026)
2.4.4.2 Global Transdermal Preparation Revenue and Market Share by Application (2021-2026)
2.4.4.3 Global Transdermal Preparation Sale Price by Application (2021-2026)
3 Global by Company
3.1 Global Transdermal Preparation Breakdown Data by Company
3.1.1 Global Transdermal Preparation Annual Sales by Company (2021-2026)
3.1.2 Global Transdermal Preparation Sales Market Share by Company (2021-2026)
3.2 Global Transdermal Preparation Annual Revenue by Company (2021-2026)
3.2.1 Global Transdermal Preparation Revenue by Company (2021-2026)
3.2.2 Global Transdermal Preparation Revenue Market Share by Company (2021-2026)
3.3 Global Transdermal Preparation Sale Price by Company
3.4 Key Manufacturers Transdermal Preparation Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Transdermal Preparation Product Location Distribution
3.4.2 Players Transdermal Preparation Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Transdermal Preparation by Geographic Region
4.1 World Historic Transdermal Preparation Market Size by Geographic Region (2021-2026)
4.1.1 Global Transdermal Preparation Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Transdermal Preparation Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Transdermal Preparation Market Size by Country/Region (2021-2026)
4.2.1 Global Transdermal Preparation Annual Sales by Country/Region (2021-2026)
4.2.2 Global Transdermal Preparation Annual Revenue by Country/Region (2021-2026)
4.3 Americas Transdermal Preparation Sales Growth
4.4 APAC Transdermal Preparation Sales Growth
4.5 Europe Transdermal Preparation Sales Growth
4.6 Middle East & Africa Transdermal Preparation Sales Growth
5 Americas
5.1 Americas Transdermal Preparation Sales by Country
5.1.1 Americas Transdermal Preparation Sales by Country (2021-2026)
5.1.2 Americas Transdermal Preparation Revenue by Country (2021-2026)
5.2 Americas Transdermal Preparation Sales by Type (2021-2026)
5.3 Americas Transdermal Preparation Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Transdermal Preparation Sales by Region
6.1.1 APAC Transdermal Preparation Sales by Region (2021-2026)
6.1.2 APAC Transdermal Preparation Revenue by Region (2021-2026)
6.2 APAC Transdermal Preparation Sales by Type (2021-2026)
6.3 APAC Transdermal Preparation Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Transdermal Preparation by Country
7.1.1 Europe Transdermal Preparation Sales by Country (2021-2026)
7.1.2 Europe Transdermal Preparation Revenue by Country (2021-2026)
7.2 Europe Transdermal Preparation Sales by Type (2021-2026)
7.3 Europe Transdermal Preparation Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Transdermal Preparation by Country
8.1.1 Middle East & Africa Transdermal Preparation Sales by Country (2021-2026)
8.1.2 Middle East & Africa Transdermal Preparation Revenue by Country (2021-2026)
8.2 Middle East & Africa Transdermal Preparation Sales by Type (2021-2026)
8.3 Middle East & Africa Transdermal Preparation Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Transdermal Preparation
10.3 Manufacturing Process Analysis of Transdermal Preparation
10.4 Industry Chain Structure of Transdermal Preparation
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Transdermal Preparation Distributors
11.3 Transdermal Preparation Customer
12 World Forecast Review for Transdermal Preparation by Geographic Region
12.1 Global Transdermal Preparation Market Size Forecast by Region
12.1.1 Global Transdermal Preparation Forecast by Region (2027-2032)
12.1.2 Global Transdermal Preparation Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Transdermal Preparation Forecast by Type (2027-2032)
12.7 Global Transdermal Preparation Forecast by Application (2027-2032)
13 Key Players Analysis
13.1 3M (US)
13.1.1 3M (US) Company Information
13.1.2 3M (US) Transdermal Preparation Product Portfolios and Specifications
13.1.3 3M (US) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 3M (US) Main Business Overview
13.1.5 3M (US) Latest Developments
13.2 AdhexPharma (FR)
13.2.1 AdhexPharma (FR) Company Information
13.2.2 AdhexPharma (FR) Transdermal Preparation Product Portfolios and Specifications
13.2.3 AdhexPharma (FR) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 AdhexPharma (FR) Main Business Overview
13.2.5 AdhexPharma (FR) Latest Developments
13.3 Bayer AG (DE)
13.3.1 Bayer AG (DE) Company Information
13.3.2 Bayer AG (DE) Transdermal Preparation Product Portfolios and Specifications
13.3.3 Bayer AG (DE) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bayer AG (DE) Main Business Overview
13.3.5 Bayer AG (DE) Latest Developments
13.4 Boehringer Ingelheim (DE)
13.4.1 Boehringer Ingelheim (DE) Company Information
13.4.2 Boehringer Ingelheim (DE) Transdermal Preparation Product Portfolios and Specifications
13.4.3 Boehringer Ingelheim (DE) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Boehringer Ingelheim (DE) Main Business Overview
13.4.5 Boehringer Ingelheim (DE) Latest Developments
13.5 Corium (US)
13.5.1 Corium (US) Company Information
13.5.2 Corium (US) Transdermal Preparation Product Portfolios and Specifications
13.5.3 Corium (US) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Corium (US) Main Business Overview
13.5.5 Corium (US) Latest Developments
13.6 Endo International (IE)
13.6.1 Endo International (IE) Company Information
13.6.2 Endo International (IE) Transdermal Preparation Product Portfolios and Specifications
13.6.3 Endo International (IE) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Endo International (IE) Main Business Overview
13.6.5 Endo International (IE) Latest Developments
13.7 GlaxoSmithKline (GSK) (GB)
13.7.1 GlaxoSmithKline (GSK) (GB) Company Information
13.7.2 GlaxoSmithKline (GSK) (GB) Transdermal Preparation Product Portfolios and Specifications
13.7.3 GlaxoSmithKline (GSK) (GB) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 GlaxoSmithKline (GSK) (GB) Main Business Overview
13.7.5 GlaxoSmithKline (GSK) (GB) Latest Developments
13.8 Grünenthal Group (DE)
13.8.1 Grünenthal Group (DE) Company Information
13.8.2 Grünenthal Group (DE) Transdermal Preparation Product Portfolios and Specifications
13.8.3 Grünenthal Group (DE) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Grünenthal Group (DE) Main Business Overview
13.8.5 Grünenthal Group (DE) Latest Developments
13.9 Henkel (DE)
13.9.1 Henkel (DE) Company Information
13.9.2 Henkel (DE) Transdermal Preparation Product Portfolios and Specifications
13.9.3 Henkel (DE) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Henkel (DE) Main Business Overview
13.9.5 Henkel (DE) Latest Developments
13.10 Hisamitsu Pharmaceutical (JP)
13.10.1 Hisamitsu Pharmaceutical (JP) Company Information
13.10.2 Hisamitsu Pharmaceutical (JP) Transdermal Preparation Product Portfolios and Specifications
13.10.3 Hisamitsu Pharmaceutical (JP) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Hisamitsu Pharmaceutical (JP) Main Business Overview
13.10.5 Hisamitsu Pharmaceutical (JP) Latest Developments
13.11 IBSA Group (CH)
13.11.1 IBSA Group (CH) Company Information
13.11.2 IBSA Group (CH) Transdermal Preparation Product Portfolios and Specifications
13.11.3 IBSA Group (CH) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 IBSA Group (CH) Main Business Overview
13.11.5 IBSA Group (CH) Latest Developments
13.12 Johnson & Johnson (US)
13.12.1 Johnson & Johnson (US) Company Information
13.12.2 Johnson & Johnson (US) Transdermal Preparation Product Portfolios and Specifications
13.12.3 Johnson & Johnson (US) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Johnson & Johnson (US) Main Business Overview
13.12.5 Johnson & Johnson (US) Latest Developments
13.13 Luye Pharma Group (HK)
13.13.1 Luye Pharma Group (HK) Company Information
13.13.2 Luye Pharma Group (HK) Transdermal Preparation Product Portfolios and Specifications
13.13.3 Luye Pharma Group (HK) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Luye Pharma Group (HK) Main Business Overview
13.13.5 Luye Pharma Group (HK) Latest Developments
13.14 LTS Lohmann Therapie-Systeme AG (DE)
13.14.1 LTS Lohmann Therapie-Systeme AG (DE) Company Information
13.14.2 LTS Lohmann Therapie-Systeme AG (DE) Transdermal Preparation Product Portfolios and Specifications
13.14.3 LTS Lohmann Therapie-Systeme AG (DE) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 LTS Lohmann Therapie-Systeme AG (DE) Main Business Overview
13.14.5 LTS Lohmann Therapie-Systeme AG (DE) Latest Developments
13.15 Mitsubishi Tanabe Pharma Corporation (JP)
13.15.1 Mitsubishi Tanabe Pharma Corporation (JP) Company Information
13.15.2 Mitsubishi Tanabe Pharma Corporation (JP) Transdermal Preparation Product Portfolios and Specifications
13.15.3 Mitsubishi Tanabe Pharma Corporation (JP) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Mitsubishi Tanabe Pharma Corporation (JP) Main Business Overview
13.15.5 Mitsubishi Tanabe Pharma Corporation (JP) Latest Developments
13.16 Mundipharma (GB)
13.16.1 Mundipharma (GB) Company Information
13.16.2 Mundipharma (GB) Transdermal Preparation Product Portfolios and Specifications
13.16.3 Mundipharma (GB) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Mundipharma (GB) Main Business Overview
13.16.5 Mundipharma (GB) Latest Developments
13.17 Mylan (Viatris) (US)
13.17.1 Mylan (Viatris) (US) Company Information
13.17.2 Mylan (Viatris) (US) Transdermal Preparation Product Portfolios and Specifications
13.17.3 Mylan (Viatris) (US) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Mylan (Viatris) (US) Main Business Overview
13.17.5 Mylan (Viatris) (US) Latest Developments
13.18 Nitto Denko Corporation (JP)
13.18.1 Nitto Denko Corporation (JP) Company Information
13.18.2 Nitto Denko Corporation (JP) Transdermal Preparation Product Portfolios and Specifications
13.18.3 Nitto Denko Corporation (JP) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Nitto Denko Corporation (JP) Main Business Overview
13.18.5 Nitto Denko Corporation (JP) Latest Developments
13.19 Noven Pharmaceuticals (US)
13.19.1 Noven Pharmaceuticals (US) Company Information
13.19.2 Noven Pharmaceuticals (US) Transdermal Preparation Product Portfolios and Specifications
13.19.3 Noven Pharmaceuticals (US) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Noven Pharmaceuticals (US) Main Business Overview
13.19.5 Noven Pharmaceuticals (US) Latest Developments
13.20 Novartis AG (CH)
13.20.1 Novartis AG (CH) Company Information
13.20.2 Novartis AG (CH) Transdermal Preparation Product Portfolios and Specifications
13.20.3 Novartis AG (CH) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Novartis AG (CH) Main Business Overview
13.20.5 Novartis AG (CH) Latest Developments
13.21 Perrigo Company plc (IE)
13.21.1 Perrigo Company plc (IE) Company Information
13.21.2 Perrigo Company plc (IE) Transdermal Preparation Product Portfolios and Specifications
13.21.3 Perrigo Company plc (IE) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Perrigo Company plc (IE) Main Business Overview
13.21.5 Perrigo Company plc (IE) Latest Developments
13.22 ProSolus, Inc. (US)
13.22.1 ProSolus, Inc. (US) Company Information
13.22.2 ProSolus, Inc. (US) Transdermal Preparation Product Portfolios and Specifications
13.22.3 ProSolus, Inc. (US) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 ProSolus, Inc. (US) Main Business Overview
13.22.5 ProSolus, Inc. (US) Latest Developments
13.23 Purdue Pharma L.P. (US)
13.23.1 Purdue Pharma L.P. (US) Company Information
13.23.2 Purdue Pharma L.P. (US) Transdermal Preparation Product Portfolios and Specifications
13.23.3 Purdue Pharma L.P. (US) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Purdue Pharma L.P. (US) Main Business Overview
13.23.5 Purdue Pharma L.P. (US) Latest Developments
13.24 Scilex Pharmaceuticals (US)
13.24.1 Scilex Pharmaceuticals (US) Company Information
13.24.2 Scilex Pharmaceuticals (US) Transdermal Preparation Product Portfolios and Specifications
13.24.3 Scilex Pharmaceuticals (US) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Scilex Pharmaceuticals (US) Main Business Overview
13.24.5 Scilex Pharmaceuticals (US) Latest Developments
13.25 Sino-American Tianjin Squibb (CN)
13.25.1 Sino-American Tianjin Squibb (CN) Company Information
13.25.2 Sino-American Tianjin Squibb (CN) Transdermal Preparation Product Portfolios and Specifications
13.25.3 Sino-American Tianjin Squibb (CN) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Sino-American Tianjin Squibb (CN) Main Business Overview
13.25.5 Sino-American Tianjin Squibb (CN) Latest Developments
13.26 SOLA Pharmaceuticals (US)
13.26.1 SOLA Pharmaceuticals (US) Company Information
13.26.2 SOLA Pharmaceuticals (US) Transdermal Preparation Product Portfolios and Specifications
13.26.3 SOLA Pharmaceuticals (US) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.26.4 SOLA Pharmaceuticals (US) Main Business Overview
13.26.5 SOLA Pharmaceuticals (US) Latest Developments
13.27 Sun Pharmaceutical Industries Ltd. (IN)
13.27.1 Sun Pharmaceutical Industries Ltd. (IN) Company Information
13.27.2 Sun Pharmaceutical Industries Ltd. (IN) Transdermal Preparation Product Portfolios and Specifications
13.27.3 Sun Pharmaceutical Industries Ltd. (IN) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.27.4 Sun Pharmaceutical Industries Ltd. (IN) Main Business Overview
13.27.5 Sun Pharmaceutical Industries Ltd. (IN) Latest Developments
13.28 Tapemark (US)
13.28.1 Tapemark (US) Company Information
13.28.2 Tapemark (US) Transdermal Preparation Product Portfolios and Specifications
13.28.3 Tapemark (US) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.28.4 Tapemark (US) Main Business Overview
13.28.5 Tapemark (US) Latest Developments
13.29 Teikoku Seiyaku Co., Ltd. (JP)
13.29.1 Teikoku Seiyaku Co., Ltd. (JP) Company Information
13.29.2 Teikoku Seiyaku Co., Ltd. (JP) Transdermal Preparation Product Portfolios and Specifications
13.29.3 Teikoku Seiyaku Co., Ltd. (JP) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.29.4 Teikoku Seiyaku Co., Ltd. (JP) Main Business Overview
13.29.5 Teikoku Seiyaku Co., Ltd. (JP) Latest Developments
13.30 Teva Pharmaceutical Industries Ltd. (IL)
13.30.1 Teva Pharmaceutical Industries Ltd. (IL) Company Information
13.30.2 Teva Pharmaceutical Industries Ltd. (IL) Transdermal Preparation Product Portfolios and Specifications
13.30.3 Teva Pharmaceutical Industries Ltd. (IL) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.30.4 Teva Pharmaceutical Industries Ltd. (IL) Main Business Overview
13.30.5 Teva Pharmaceutical Industries Ltd. (IL) Latest Developments
13.31 UCB Pharma (BE)
13.31.1 UCB Pharma (BE) Company Information
13.31.2 UCB Pharma (BE) Transdermal Preparation Product Portfolios and Specifications
13.31.3 UCB Pharma (BE) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.31.4 UCB Pharma (BE) Main Business Overview
13.31.5 UCB Pharma (BE) Latest Developments
13.32 Upsher-Smith Laboratories (US)
13.32.1 Upsher-Smith Laboratories (US) Company Information
13.32.2 Upsher-Smith Laboratories (US) Transdermal Preparation Product Portfolios and Specifications
13.32.3 Upsher-Smith Laboratories (US) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.32.4 Upsher-Smith Laboratories (US) Main Business Overview
13.32.5 Upsher-Smith Laboratories (US) Latest Developments
13.33 Henan Lingrui Pharmaceutical Co., Ltd. (CN)
13.33.1 Henan Lingrui Pharmaceutical Co., Ltd. (CN) Company Information
13.33.2 Henan Lingrui Pharmaceutical Co., Ltd. (CN) Transdermal Preparation Product Portfolios and Specifications
13.33.3 Henan Lingrui Pharmaceutical Co., Ltd. (CN) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.33.4 Henan Lingrui Pharmaceutical Co., Ltd. (CN) Main Business Overview
13.33.5 Henan Lingrui Pharmaceutical Co., Ltd. (CN) Latest Developments
13.34 Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN)
13.34.1 Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN) Company Information
13.34.2 Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN) Transdermal Preparation Product Portfolios and Specifications
13.34.3 Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN) Transdermal Preparation Sales, Revenue, Price and Gross Margin (2021-2026)
13.34.4 Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN) Main Business Overview
13.34.5 Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN) Latest Developments
14 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Transdermal Preparation Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Transdermal Preparation Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Injectable Preparations
Table 4. Major Players of Non Injectable Preparations
Table 5. Global Transdermal Preparation Sales by Type (2021-2026) & (K Units)
Table 6. Global Transdermal Preparation Sales Market Share by Type (2021-2026)
Table 7. Global Transdermal Preparation Revenue by Type (2021-2026) & ($ million)
Table 8. Global Transdermal Preparation Revenue Market Share by Type (2021-2026)
Table 9. Global Transdermal Preparation Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Patch
Table 11. Major Players of Cataplasm Hydrogel Patch
Table 12. Major Players of Hot Melt Adhesive Patch
Table 13. Major Players of Other
Table 14. Global Transdermal Preparation Sales by Dosage Form (2021-2026) & (K Units)
Table 15. Global Transdermal Preparation Sales Market Share by Dosage Form (2021-2026)
Table 16. Global Transdermal Preparation Revenue by Dosage Form (2021-2026) & ($ million)
Table 17. Global Transdermal Preparation Revenue Market Share by Dosage Form (2021-2026)
Table 18. Global Transdermal Preparation Sale Price by Dosage Form (2021-2026) & (US$/Unit)
Table 19. Major Players of ＜ 12.5 μg/h
Table 20. Major Players of 12.5 – 25 μg/h
Table 21. Major Players of 25 – 50 μg/h
Table 22. Major Players of 50 – 100 μg/h
Table 23. Major Players of ＞ 100 μg/h
Table 24. Global Transdermal Preparation Sale by Application (2021-2026) & (K Units)
Table 25. Global Transdermal Preparation Sale Market Share by Application (2021-2026)
Table 26. Global Transdermal Preparation Revenue by Application (2021-2026) & ($ million)
Table 27. Global Transdermal Preparation Revenue Market Share by Application (2021-2026)
Table 28. Global Transdermal Preparation Sale Price by Application (2021-2026) & (US$/Unit)
Table 29. Global Transdermal Preparation Sales by Company (2021-2026) & (K Units)
Table 30. Global Transdermal Preparation Sales Market Share by Company (2021-2026)
Table 31. Global Transdermal Preparation Revenue by Company (2021-2026) & ($ millions)
Table 32. Global Transdermal Preparation Revenue Market Share by Company (2021-2026)
Table 33. Global Transdermal Preparation Sale Price by Company (2021-2026) & (US$/Unit)
Table 34. Key Manufacturers Transdermal Preparation Producing Area Distribution and Sales Area
Table 35. Players Transdermal Preparation Products Offered
Table 36. Transdermal Preparation Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 37. New Products and Potential Entrants
Table 38. Market M&A Activity & Strategy
Table 39. Global Transdermal Preparation Sales by Geographic Region (2021-2026) & (K Units)
Table 40. Global Transdermal Preparation Sales Market Share Geographic Region (2021-2026)
Table 41. Global Transdermal Preparation Revenue by Geographic Region (2021-2026) & ($ millions)
Table 42. Global Transdermal Preparation Revenue Market Share by Geographic Region (2021-2026)
Table 43. Global Transdermal Preparation Sales by Country/Region (2021-2026) & (K Units)
Table 44. Global Transdermal Preparation Sales Market Share by Country/Region (2021-2026)
Table 45. Global Transdermal Preparation Revenue by Country/Region (2021-2026) & ($ millions)
Table 46. Global Transdermal Preparation Revenue Market Share by Country/Region (2021-2026)
Table 47. Americas Transdermal Preparation Sales by Country (2021-2026) & (K Units)
Table 48. Americas Transdermal Preparation Sales Market Share by Country (2021-2026)
Table 49. Americas Transdermal Preparation Revenue by Country (2021-2026) & ($ millions)
Table 50. Americas Transdermal Preparation Sales by Type (2021-2026) & (K Units)
Table 51. Americas Transdermal Preparation Sales by Application (2021-2026) & (K Units)
Table 52. APAC Transdermal Preparation Sales by Region (2021-2026) & (K Units)
Table 53. APAC Transdermal Preparation Sales Market Share by Region (2021-2026)
Table 54. APAC Transdermal Preparation Revenue by Region (2021-2026) & ($ millions)
Table 55. APAC Transdermal Preparation Sales by Type (2021-2026) & (K Units)
Table 56. APAC Transdermal Preparation Sales by Application (2021-2026) & (K Units)
Table 57. Europe Transdermal Preparation Sales by Country (2021-2026) & (K Units)
Table 58. Europe Transdermal Preparation Revenue by Country (2021-2026) & ($ millions)
Table 59. Europe Transdermal Preparation Sales by Type (2021-2026) & (K Units)
Table 60. Europe Transdermal Preparation Sales by Application (2021-2026) & (K Units)
Table 61. Middle East & Africa Transdermal Preparation Sales by Country (2021-2026) & (K Units)
Table 62. Middle East & Africa Transdermal Preparation Revenue Market Share by Country (2021-2026)
Table 63. Middle East & Africa Transdermal Preparation Sales by Type (2021-2026) & (K Units)
Table 64. Middle East & Africa Transdermal Preparation Sales by Application (2021-2026) & (K Units)
Table 65. Key Market Drivers & Growth Opportunities of Transdermal Preparation
Table 66. Key Market Challenges & Risks of Transdermal Preparation
Table 67. Key Industry Trends of Transdermal Preparation
Table 68. Transdermal Preparation Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Transdermal Preparation Distributors List
Table 71. Transdermal Preparation Customer List
Table 72. Global Transdermal Preparation Sales Forecast by Region (2027-2032) & (K Units)
Table 73. Global Transdermal Preparation Revenue Forecast by Region (2027-2032) & ($ millions)
Table 74. Americas Transdermal Preparation Sales Forecast by Country (2027-2032) & (K Units)
Table 75. Americas Transdermal Preparation Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 76. APAC Transdermal Preparation Sales Forecast by Region (2027-2032) & (K Units)
Table 77. APAC Transdermal Preparation Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Europe Transdermal Preparation Sales Forecast by Country (2027-2032) & (K Units)
Table 79. Europe Transdermal Preparation Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. Middle East & Africa Transdermal Preparation Sales Forecast by Country (2027-2032) & (K Units)
Table 81. Middle East & Africa Transdermal Preparation Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Global Transdermal Preparation Sales Forecast by Type (2027-2032) & (K Units)
Table 83. Global Transdermal Preparation Revenue Forecast by Type (2027-2032) & ($ millions)
Table 84. Global Transdermal Preparation Sales Forecast by Application (2027-2032) & (K Units)
Table 85. Global Transdermal Preparation Revenue Forecast by Application (2027-2032) & ($ millions)
Table 86. 3M (US) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 87. 3M (US) Transdermal Preparation Product Portfolios and Specifications
Table 88. 3M (US) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. 3M (US) Main Business
Table 90. 3M (US) Latest Developments
Table 91. AdhexPharma (FR) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 92. AdhexPharma (FR) Transdermal Preparation Product Portfolios and Specifications
Table 93. AdhexPharma (FR) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. AdhexPharma (FR) Main Business
Table 95. AdhexPharma (FR) Latest Developments
Table 96. Bayer AG (DE) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 97. Bayer AG (DE) Transdermal Preparation Product Portfolios and Specifications
Table 98. Bayer AG (DE) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Bayer AG (DE) Main Business
Table 100. Bayer AG (DE) Latest Developments
Table 101. Boehringer Ingelheim (DE) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 102. Boehringer Ingelheim (DE) Transdermal Preparation Product Portfolios and Specifications
Table 103. Boehringer Ingelheim (DE) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Boehringer Ingelheim (DE) Main Business
Table 105. Boehringer Ingelheim (DE) Latest Developments
Table 106. Corium (US) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 107. Corium (US) Transdermal Preparation Product Portfolios and Specifications
Table 108. Corium (US) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Corium (US) Main Business
Table 110. Corium (US) Latest Developments
Table 111. Endo International (IE) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 112. Endo International (IE) Transdermal Preparation Product Portfolios and Specifications
Table 113. Endo International (IE) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. Endo International (IE) Main Business
Table 115. Endo International (IE) Latest Developments
Table 116. GlaxoSmithKline (GSK) (GB) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 117. GlaxoSmithKline (GSK) (GB) Transdermal Preparation Product Portfolios and Specifications
Table 118. GlaxoSmithKline (GSK) (GB) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. GlaxoSmithKline (GSK) (GB) Main Business
Table 120. GlaxoSmithKline (GSK) (GB) Latest Developments
Table 121. Grünenthal Group (DE) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 122. Grünenthal Group (DE) Transdermal Preparation Product Portfolios and Specifications
Table 123. Grünenthal Group (DE) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. Grünenthal Group (DE) Main Business
Table 125. Grünenthal Group (DE) Latest Developments
Table 126. Henkel (DE) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 127. Henkel (DE) Transdermal Preparation Product Portfolios and Specifications
Table 128. Henkel (DE) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. Henkel (DE) Main Business
Table 130. Henkel (DE) Latest Developments
Table 131. Hisamitsu Pharmaceutical (JP) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 132. Hisamitsu Pharmaceutical (JP) Transdermal Preparation Product Portfolios and Specifications
Table 133. Hisamitsu Pharmaceutical (JP) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Hisamitsu Pharmaceutical (JP) Main Business
Table 135. Hisamitsu Pharmaceutical (JP) Latest Developments
Table 136. IBSA Group (CH) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 137. IBSA Group (CH) Transdermal Preparation Product Portfolios and Specifications
Table 138. IBSA Group (CH) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. IBSA Group (CH) Main Business
Table 140. IBSA Group (CH) Latest Developments
Table 141. Johnson & Johnson (US) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 142. Johnson & Johnson (US) Transdermal Preparation Product Portfolios and Specifications
Table 143. Johnson & Johnson (US) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 144. Johnson & Johnson (US) Main Business
Table 145. Johnson & Johnson (US) Latest Developments
Table 146. Luye Pharma Group (HK) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 147. Luye Pharma Group (HK) Transdermal Preparation Product Portfolios and Specifications
Table 148. Luye Pharma Group (HK) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 149. Luye Pharma Group (HK) Main Business
Table 150. Luye Pharma Group (HK) Latest Developments
Table 151. LTS Lohmann Therapie-Systeme AG (DE) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 152. LTS Lohmann Therapie-Systeme AG (DE) Transdermal Preparation Product Portfolios and Specifications
Table 153. LTS Lohmann Therapie-Systeme AG (DE) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 154. LTS Lohmann Therapie-Systeme AG (DE) Main Business
Table 155. LTS Lohmann Therapie-Systeme AG (DE) Latest Developments
Table 156. Mitsubishi Tanabe Pharma Corporation (JP) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 157. Mitsubishi Tanabe Pharma Corporation (JP) Transdermal Preparation Product Portfolios and Specifications
Table 158. Mitsubishi Tanabe Pharma Corporation (JP) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 159. Mitsubishi Tanabe Pharma Corporation (JP) Main Business
Table 160. Mitsubishi Tanabe Pharma Corporation (JP) Latest Developments
Table 161. Mundipharma (GB) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 162. Mundipharma (GB) Transdermal Preparation Product Portfolios and Specifications
Table 163. Mundipharma (GB) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 164. Mundipharma (GB) Main Business
Table 165. Mundipharma (GB) Latest Developments
Table 166. Mylan (Viatris) (US) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 167. Mylan (Viatris) (US) Transdermal Preparation Product Portfolios and Specifications
Table 168. Mylan (Viatris) (US) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 169. Mylan (Viatris) (US) Main Business
Table 170. Mylan (Viatris) (US) Latest Developments
Table 171. Nitto Denko Corporation (JP) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 172. Nitto Denko Corporation (JP) Transdermal Preparation Product Portfolios and Specifications
Table 173. Nitto Denko Corporation (JP) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 174. Nitto Denko Corporation (JP) Main Business
Table 175. Nitto Denko Corporation (JP) Latest Developments
Table 176. Noven Pharmaceuticals (US) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 177. Noven Pharmaceuticals (US) Transdermal Preparation Product Portfolios and Specifications
Table 178. Noven Pharmaceuticals (US) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 179. Noven Pharmaceuticals (US) Main Business
Table 180. Noven Pharmaceuticals (US) Latest Developments
Table 181. Novartis AG (CH) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 182. Novartis AG (CH) Transdermal Preparation Product Portfolios and Specifications
Table 183. Novartis AG (CH) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 184. Novartis AG (CH) Main Business
Table 185. Novartis AG (CH) Latest Developments
Table 186. Perrigo Company plc (IE) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 187. Perrigo Company plc (IE) Transdermal Preparation Product Portfolios and Specifications
Table 188. Perrigo Company plc (IE) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 189. Perrigo Company plc (IE) Main Business
Table 190. Perrigo Company plc (IE) Latest Developments
Table 191. ProSolus, Inc. (US) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 192. ProSolus, Inc. (US) Transdermal Preparation Product Portfolios and Specifications
Table 193. ProSolus, Inc. (US) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 194. ProSolus, Inc. (US) Main Business
Table 195. ProSolus, Inc. (US) Latest Developments
Table 196. Purdue Pharma L.P. (US) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 197. Purdue Pharma L.P. (US) Transdermal Preparation Product Portfolios and Specifications
Table 198. Purdue Pharma L.P. (US) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 199. Purdue Pharma L.P. (US) Main Business
Table 200. Purdue Pharma L.P. (US) Latest Developments
Table 201. Scilex Pharmaceuticals (US) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 202. Scilex Pharmaceuticals (US) Transdermal Preparation Product Portfolios and Specifications
Table 203. Scilex Pharmaceuticals (US) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 204. Scilex Pharmaceuticals (US) Main Business
Table 205. Scilex Pharmaceuticals (US) Latest Developments
Table 206. Sino-American Tianjin Squibb (CN) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 207. Sino-American Tianjin Squibb (CN) Transdermal Preparation Product Portfolios and Specifications
Table 208. Sino-American Tianjin Squibb (CN) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 209. Sino-American Tianjin Squibb (CN) Main Business
Table 210. Sino-American Tianjin Squibb (CN) Latest Developments
Table 211. SOLA Pharmaceuticals (US) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 212. SOLA Pharmaceuticals (US) Transdermal Preparation Product Portfolios and Specifications
Table 213. SOLA Pharmaceuticals (US) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 214. SOLA Pharmaceuticals (US) Main Business
Table 215. SOLA Pharmaceuticals (US) Latest Developments
Table 216. Sun Pharmaceutical Industries Ltd. (IN) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 217. Sun Pharmaceutical Industries Ltd. (IN) Transdermal Preparation Product Portfolios and Specifications
Table 218. Sun Pharmaceutical Industries Ltd. (IN) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 219. Sun Pharmaceutical Industries Ltd. (IN) Main Business
Table 220. Sun Pharmaceutical Industries Ltd. (IN) Latest Developments
Table 221. Tapemark (US) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 222. Tapemark (US) Transdermal Preparation Product Portfolios and Specifications
Table 223. Tapemark (US) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 224. Tapemark (US) Main Business
Table 225. Tapemark (US) Latest Developments
Table 226. Teikoku Seiyaku Co., Ltd. (JP) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 227. Teikoku Seiyaku Co., Ltd. (JP) Transdermal Preparation Product Portfolios and Specifications
Table 228. Teikoku Seiyaku Co., Ltd. (JP) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 229. Teikoku Seiyaku Co., Ltd. (JP) Main Business
Table 230. Teikoku Seiyaku Co., Ltd. (JP) Latest Developments
Table 231. Teva Pharmaceutical Industries Ltd. (IL) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 232. Teva Pharmaceutical Industries Ltd. (IL) Transdermal Preparation Product Portfolios and Specifications
Table 233. Teva Pharmaceutical Industries Ltd. (IL) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 234. Teva Pharmaceutical Industries Ltd. (IL) Main Business
Table 235. Teva Pharmaceutical Industries Ltd. (IL) Latest Developments
Table 236. UCB Pharma (BE) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 237. UCB Pharma (BE) Transdermal Preparation Product Portfolios and Specifications
Table 238. UCB Pharma (BE) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 239. UCB Pharma (BE) Main Business
Table 240. UCB Pharma (BE) Latest Developments
Table 241. Upsher-Smith Laboratories (US) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 242. Upsher-Smith Laboratories (US) Transdermal Preparation Product Portfolios and Specifications
Table 243. Upsher-Smith Laboratories (US) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 244. Upsher-Smith Laboratories (US) Main Business
Table 245. Upsher-Smith Laboratories (US) Latest Developments
Table 246. Henan Lingrui Pharmaceutical Co., Ltd. (CN) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 247. Henan Lingrui Pharmaceutical Co., Ltd. (CN) Transdermal Preparation Product Portfolios and Specifications
Table 248. Henan Lingrui Pharmaceutical Co., Ltd. (CN) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 249. Henan Lingrui Pharmaceutical Co., Ltd. (CN) Main Business
Table 250. Henan Lingrui Pharmaceutical Co., Ltd. (CN) Latest Developments
Table 251. Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN) Basic Information, Transdermal Preparation Manufacturing Base, Sales Area and Its Competitors
Table 252. Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN) Transdermal Preparation Product Portfolios and Specifications
Table 253. Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN) Transdermal Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 254. Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN) Main Business
Table 255. Zhejiang Jingxin Pharmaceutical Co., Ltd. (CN) Latest Developments


List of Figures
Figure 1. Picture of Transdermal Preparation
Figure 2. Transdermal Preparation Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Transdermal Preparation Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Transdermal Preparation Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Transdermal Preparation Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Transdermal Preparation Sales Market Share by Country/Region (2025)
Figure 10. Transdermal Preparation Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Injectable Preparations
Figure 12. Product Picture of Non Injectable Preparations
Figure 13. Global Transdermal Preparation Sales Market Share by Type in 2026
Figure 14. Global Transdermal Preparation Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Patch
Figure 16. Product Picture of Cataplasm Hydrogel Patch
Figure 17. Product Picture of Hot Melt Adhesive Patch
Figure 18. Product Picture of Other
Figure 19. Global Transdermal Preparation Sales Market Share by Dosage Form in 2026
Figure 20. Global Transdermal Preparation Revenue Market Share by Dosage Form (2021-2026)
Figure 21. Product Picture of ＜ 12.5 μg/h
Figure 22. Product Picture of 12.5 – 25 μg/h
Figure 23. Product Picture of 25 – 50 μg/h
Figure 24. Product Picture of 50 – 100 μg/h
Figure 25. Product Picture of ＞ 100 μg/h
Figure 26. Transdermal Preparation Consumed in Hospital
Figure 27. Global Transdermal Preparation Market: Hospital (2021-2026) & (K Units)
Figure 28. Transdermal Preparation Consumed in Clinic
Figure 29. Global Transdermal Preparation Market: Clinic (2021-2026) & (K Units)
Figure 30. Transdermal Preparation Consumed in Other
Figure 31. Global Transdermal Preparation Market: Other (2021-2026) & (K Units)
Figure 32. Global Transdermal Preparation Sale Market Share by Application (2025)
Figure 33. Global Transdermal Preparation Revenue Market Share by Application in 2025
Figure 34. Transdermal Preparation Sales by Company in 2025 (K Units)
Figure 35. Global Transdermal Preparation Sales Market Share by Company in 2025
Figure 36. Transdermal Preparation Revenue by Company in 2025 ($ millions)
Figure 37. Global Transdermal Preparation Revenue Market Share by Company in 2025
Figure 38. Global Transdermal Preparation Sales Market Share by Geographic Region (2021-2026)
Figure 39. Global Transdermal Preparation Revenue Market Share by Geographic Region in 2025
Figure 40. Americas Transdermal Preparation Sales 2021-2026 (K Units)
Figure 41. Americas Transdermal Preparation Revenue 2021-2026 ($ millions)
Figure 42. APAC Transdermal Preparation Sales 2021-2026 (K Units)
Figure 43. APAC Transdermal Preparation Revenue 2021-2026 ($ millions)
Figure 44. Europe Transdermal Preparation Sales 2021-2026 (K Units)
Figure 45. Europe Transdermal Preparation Revenue 2021-2026 ($ millions)
Figure 46. Middle East & Africa Transdermal Preparation Sales 2021-2026 (K Units)
Figure 47. Middle East & Africa Transdermal Preparation Revenue 2021-2026 ($ millions)
Figure 48. Americas Transdermal Preparation Sales Market Share by Country in 2025
Figure 49. Americas Transdermal Preparation Revenue Market Share by Country (2021-2026)
Figure 50. Americas Transdermal Preparation Sales Market Share by Type (2021-2026)
Figure 51. Americas Transdermal Preparation Sales Market Share by Application (2021-2026)
Figure 52. United States Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 53. Canada Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 54. Mexico Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 55. Brazil Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 56. APAC Transdermal Preparation Sales Market Share by Region in 2025
Figure 57. APAC Transdermal Preparation Revenue Market Share by Region (2021-2026)
Figure 58. APAC Transdermal Preparation Sales Market Share by Type (2021-2026)
Figure 59. APAC Transdermal Preparation Sales Market Share by Application (2021-2026)
Figure 60. China Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 61. Japan Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 62. South Korea Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 63. Southeast Asia Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 64. India Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 65. Australia Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 66. China Taiwan Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 67. Europe Transdermal Preparation Sales Market Share by Country in 2025
Figure 68. Europe Transdermal Preparation Revenue Market Share by Country (2021-2026)
Figure 69. Europe Transdermal Preparation Sales Market Share by Type (2021-2026)
Figure 70. Europe Transdermal Preparation Sales Market Share by Application (2021-2026)
Figure 71. Germany Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 72. France Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 73. UK Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 74. Italy Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 75. Russia Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 76. Middle East & Africa Transdermal Preparation Sales Market Share by Country (2021-2026)
Figure 77. Middle East & Africa Transdermal Preparation Sales Market Share by Type (2021-2026)
Figure 78. Middle East & Africa Transdermal Preparation Sales Market Share by Application (2021-2026)
Figure 79. Egypt Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 80. South Africa Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 81. Israel Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 82. Turkey Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 83. GCC Countries Transdermal Preparation Revenue Growth 2021-2026 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Transdermal Preparation in 2026
Figure 85. Manufacturing Process Analysis of Transdermal Preparation
Figure 86. Industry Chain Structure of Transdermal Preparation
Figure 87. Channels of Distribution
Figure 88. Global Transdermal Preparation Sales Market Forecast by Region (2027-2032)
Figure 89. Global Transdermal Preparation Revenue Market Share Forecast by Region (2027-2032)
Figure 90. Global Transdermal Preparation Sales Market Share Forecast by Type (2027-2032)
Figure 91. Global Transdermal Preparation Revenue Market Share Forecast by Type (2027-2032)
Figure 92. Global Transdermal Preparation Sales Market Share Forecast by Application (2027-2032)
Figure 93. Global Transdermal Preparation Revenue Market Share Forecast by Application (2027-2032)